A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1

Area of Science:

• Immunology
• Hematology
• Oncology

Background:

• Plasma cells are crucial in humoral immunity.
• Multiple myeloma is a hematological malignancy characterized by malignant plasma cells.
• Accurate identification of plasma cells is vital for diagnosis and treatment.

Purpose of the Study:

• To develop and characterize a novel monoclonal antibody for specific human plasma cell identification.
• To evaluate the utility of the new antibody in diagnosing multiple myeloma and other hematological malignancies.
• To explore the potential application of the antibody in cell-based therapies.

Main Methods:

• Development of a new monoclonal antibody, designated B-B4.
• Testing the reactivity of B-B4 against various human cell types, including multiple myeloma cell lines and patient samples.
• Immunohistochemical analysis of tumor samples.
• Antigen cloning to identify the target recognized by B-B4.

Main Results:

• The B-B4 antibody specifically identifies human plasma cells.
• B-B4 strongly reacts with multiple myeloma cell lines and malignant plasma cells from patients.
• No reactivity was observed with peripheral blood, bone marrow, or tonsil cells.
• The B-B4 antigen was identified as syndecan-1.
• The antibody showed potential for use in depletions prior to CD34 grafting.

Conclusions:

• The monoclonal antibody B-B4 is a suitable and specific marker for human plasma cells.
• B-B4 is a valuable tool for the diagnosis of hematological malignancies, particularly multiple myeloma.
• B-B4 has potential applications in cell-based therapies, such as prior to CD34 grafting.